Navigation Links
Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia

PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - Affymax, Inc. (Nasdaq:AFFY) today announced that additional Phase 2 clinical trial results for Hematide(TM) were presented at the European Renal Association-EDTA Congress being held in Barcelona, Spain by Iain C. Macdougall, M.D., a Hematide investigator from Kings College, London. Dr. Macdougall's poster included data in previously-treated dialysis patients and treatment naive, non-dialysis patients which demonstrated that mean hemoglobin (Hgb) levels could be maintained and corrected, respectively, with once monthly Hematide.

Specifically, the data showed that in non-dialysis patients an initial range of doses from .025 mg/kg to .075 mg/kg of Hematide, in conjunction with dose adjustments, is adequate to increase Hgb in anemic patients with renal failure when administered monthly. In addition, intravenous and subcutaneous dosing appeared to result in a similar Hgb increase.

"These data support further investigation of the versatility and flexibility of once-per-month Hematide in terms of starting doses and route of administration," said Robert Naso, Ph.D., executive vice president of Research and Development at Affymax. "These results demonstrate that a narrow target range of hemoglobin levels can be reached with different initial Hematide doses. We are pleased to have such thorough evaluation of the product as we prepare for pivotal Phase 3 clinical trials."

At the time of the presentation, the data generated to date were from two multi-center, open-label studies that have enrolled a total of 304 patients. Safety data were based on the entire patient population, while pharmacodynamic data were based on 179 patients who had mostly completed six months of treatment at European and U.S. clinical sites. Of those, 89 treatment-naive CKD patients who were not on dialysis in the correction study were treated with Hematide once every four weeks. The me
'"/>




Page: 1 2 3

Related medicine technology :

1. Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide for the Treatment of Anemia in Patients with Early- and End-Stage Chronic Kidney Disease
2. Affymax Announces Results From Phase 2 Clinical Trial of Hematide for the Treatment of Anemia in Dialysis Patients
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:6/30/2015)... -- Pulse Light Clinic in London,s ... as part of their ongoing research into the condition. They ... their Rosacea. The survey participants were aged between 20 and ... women. The results revealed some rather surprising statistics: ... attempt to visit their GP for Rosacea treatment. ...
(Date:6/30/2015)... 30, 2015 First Choice Wellness Care recently ... Duality and is the only clinic in the greater ... removal treatments. The practice has recently expanded their services ... to showcase their focus in the procedure. They upgraded ... faster ink clearance, and superior service. "We,ve ...
(Date:6/30/2015)... 2015  Avanir Pharmaceuticals, Inc. today announced top-line ... treatment with NUEDEXTA ® was associated with ... affect (PBA) in patients with traumatic brain injury ... characterized by sudden and uncontrollable outbursts of laughing ... brain injury. PRISM II is a phase IV ...
Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 2First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7
... 2011 Fuisz ( www.fuisz.com ) today announced the ... Permitting Stage Door Access to On-Line Vendor Information"). ... "This patent covers a system that allows a customer ... a product supplier database through the on-line vendor,s system ...
... 15, 2011 Cardium Therapeutics (NYSE Amex: ... from the Russian Ministry of Health and Social Development ... Company,s Generx™ (alferminogene tadenovec, Ad5FGF-4) biologic product candidate.  Generx ... for the potential treatment of myocardial ischemia due to ...
Cached Medicine Technology:Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 2Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 3Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 4Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 5Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 6Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease 7
(Date:6/30/2015)... ... June 30, 2015 , ... ... joined Allegheny Health Network (AHN) as Director of its Adult Neuro-Oncology ... of primary brain tumors, brain metastases, leptomeningeal disease and the neurological complications of ...
(Date:6/30/2015)... ... June 30, 2015 , ... Harbor Village Detox ... addiction care in Florida on June 12th. Holly Vasquez-Cortella was recently quoted as ... a website dedicated to reporting on trending addiction news and treatment innovations. The article ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... most advanced protection at less thickness than any other padding in football. , ... impact protection and shock absorption, Gameday Armour is engineered with D3O protective polymer. ...
(Date:6/30/2015)... ... 30, 2015 , ... It has become fairly common to purchase fresh broccoli ... the stalks before cooking. Throwing out radish greens, beet leaves and chard stalks is ... It just takes a little knowledge and practice to use them. Josie's Organics ...
(Date:6/30/2015)... ... June 30, 2015 , ... Skin Brushing (also known as Body Brushing) is a wonderful ... and beautiful as it is more exposed to the elements. , Dry Skin Brushing takes ... Exfoliate the dead cells and toxins on skin's surface. Skin is the largest ...
Breaking Medicine News(10 mins):Health News:Noted Duke Brain Cancer Specialist to Direct Allegheny Health Network Neuro-Oncology Program 2Health News:Noted Duke Brain Cancer Specialist to Direct Allegheny Health Network Neuro-Oncology Program 3Health News:Harbor Village Detox’s Clinical Director Is Quoted as an Addiction Expert by The Fix 2Health News:Harbor Village Detox’s Clinical Director Is Quoted as an Addiction Expert by The Fix 3Health News:Under Armour Launches Advanced Gameday Armour® Max Protection System For The Gridiron 2Health News:Whole Vegetable Cooking for Home Cooks: Josie's Organics Encourages Using All Parts of Vegetables – from Root to Stalk – Every Day 2Health News:Whole Vegetable Cooking for Home Cooks: Josie's Organics Encourages Using All Parts of Vegetables – from Root to Stalk – Every Day 3Health News:Whole Vegetable Cooking for Home Cooks: Josie's Organics Encourages Using All Parts of Vegetables – from Root to Stalk – Every Day 4Health News:Back in Stock: Keep Skin and Lymphatic System Healthy with Dry Skin Brushes from Sublime Beauty® 2
... ... Opportunities Report, public and private healthcare providers will be able to save between $1.96 ... using cellular networks by the year 2014. , ... Hampshire, UK (PRWEB) May 11, 2010 -- ...
... ... Reconstructive, & Laser Surgery and Benjamin C. Stong MD are proud to be the first ... skin resurfacing technology. , ... May 11, 2010 -- Kalos: The Atlanta Center for Facial Plastic, Reconstructive, & Laser Surgery ...
... When patients present with chest pain or other high-risk ... imaging and computed tomography (CT) tests to find out ... the coronary arteries or reduced blood flow to the ... prevention and treatment options. However, despite their ...
... are the fundamental differences between cancer cells and normal ... is that the biological clocks in cancer cells are ... that they do in normal cells. This assumption ... that has continuously monitored variations in the rate of ...
... movement disorder, study shows , MONDAY, May 10 (HealthDay News) ... legs syndrome are also more likely to suffer from the ... study, which is published in the May issue of ... of the condition for both physicians and patients. , "These ...
... ... syndrome , ... 2010 -- One person can make a difference, one dollar at a time: that’s the ... center for people with Trisomy 21 (better known as Down syndrome). Launched one week ago ...
Cached Medicine News:Health News:Cost Savings from Mobile Health Monitoring to Reach $1.9 billion to $5.8 Billion Globally by 2014 says Juniper Research 2Health News:Cost Savings from Mobile Health Monitoring to Reach $1.9 billion to $5.8 Billion Globally by 2014 says Juniper Research 3Health News:Kalos: Facial Plastic Surgery Brings the Pearl Fractional Laser to Atlanta 2Health News:Concerns over radiation exposure may overshadow life-saving benefits of cardiac imaging tests 2Health News:Concerns over radiation exposure may overshadow life-saving benefits of cardiac imaging tests 3Health News:Concerns over radiation exposure may overshadow life-saving benefits of cardiac imaging tests 4Health News:How cancer cells loose their (Circadian) rhythm 2Health News:Restless Legs Syndrome Can Have Family Ties 2Health News:Charity Asks for $1 2
... D-Type can combine a number of ... microplates on a simple to use ... is a multifunctional stand-alone device but ... robotic systems. Custom and standard add-on ...
Grab one and go, One of the smallest handheld oximeters available, Datex-Ohmeda s TuffSat is the ideal spot-check solution for hospital, home care, transport, and EMS. TuffSat comes fully loaded wi...
Smith & Nephew's CDS System is developed exclusively for discography., Developed exclusively for discography, it is the first system designed to measure true disc pressure and record real-time proce...
The Maxi-Therm® lite hyper-hypothermia water blankets from Cincinnati Sub-Zero take conductive warming and cooling therapy to a new, softer level. These blankets are soft, lightweight, and remai...
Medicine Products: